Rett Syndrome Market Insights, Epidemiology Segmentation, and Market Report

DelveInsight’s Rett syndrome Market Insights report provides a thorough understanding of current treatment practices, emerging Rett syndrome market share of the individual therapies, current and forecasted Rett syndrome market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Rett syndrome Overview

Rett syndrome is a unique neurodevelopmental disorder that is first noticed in infancy and primarily affects girls, but can be rarely seen in boys. It is caused by mutations on the X-chromosome on a gene called MECP2. There are more than 200 different mutations found on the MECP2 gene. Most of these mutations are found in eight different “hot spots.” Rett syndrome is mostly misdiagnosed as autism, cerebral palsy, or global developmental delay. It is found in all ethnic and racial groups.

 

Get an overview of the report @ Rett syndrome Market Report

 

Some of the key highlights of the Rett Syndrome Market Report

Through various secondary resources, it can be concluded that Rett Syndrome basically affects females and is rarely seen in males.
Rett Syndrome is estimated to affect about one in 12,000 girls born each year and is only rarely seen in males.
Approximately 85-90% of affected people may experience growth failure and muscle wasting that worsens with age.
Rett Syndrome companies included such as Acadia Pharmaceuticals, GW Research, and several others.
Rett Syndrome therapies included such as NNZ-2566 (Trofinetide), Epidiolex, and several others.

 

Rett Syndrome Symptoms

Slowed growth. Brain growth slows after birth
Loss of normal movement and coordination
Loss of communication abilities
Abnormal hand movements
Unusual eye movements
Breathing problems
Irritability and crying
Other abnormal behaviors

 

Rett Syndrome Causes

Rett syndrome is not a degenerative disorder but causes problems in brain function that are responsible for cognitive, sensory, emotional, motor and autonomic function. These can include learning, speech, sensory sensations, mood, movement, breathing, cardiac function, and even chewing, swallowing, and digestion. Rett syndrome is part of a spectrum of disorders with the same genetic cause. Other disorders on the spectrum include PPM-X syndrome, MECP2 duplication syndrome, and MECP2-related severe neonatal encephalopathy. These other conditions can affect males.

 

Rett Syndrome Treatment

Currently, the treatment paradigm for Rett Syndrome includes few treatment options, which are generally supportive in nature such as physical therapy, hydrotherapy, occupational therapy, speech-language therapy and medications and diet management. However, various off-label drugs are used for palliative treatment of Rett Syndrome which include bromocriptine, carbidopa-levodopa, levocarnitine, and certain antidepressants such as trazodone can also be prescribed to ease sleep related problems.

 

Get in-depth information on Rett Syndrome Market Share

 

Rett Syndrome Market Insights

Rett syndrome Treatment is symptomatic, i.e., focusing on the management of symptoms that require a multidisciplinary approach. Treatment basically is categorized into physical therapy, hydrotherapy, occupational therapy, speech-language therapy and medications.

 

Rett Syndrome Emerging Therapy Assessment

 The dynamics of Rett Syndrome market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are several key players involved in developing the therapies for Rett Syndrome like Neuren Pharmaceuticals/Acadia Pharmaceuticals (NNZ-2566), GW Research (GWP42003-P), Anavex Life Sciences (Anavex 2-73), Ultragenyx Pharmaceutical (Dojolvi) and others. The launch of emerging therapies is expected during the forecast period of 2021-2030.

 

Rett Syndrome Market Report Highlights

In more than 99% of people with Rett syndrome, there is no history of the disorder in their family. Many of these cases result from new mutations in the MECP2 gene. More than 200 different mutations have been identified in this gene. This disease is caused by a genetic mutation on the long arm of the X chromosome. These genes cause the brain to develop incorrectly by inappropriately activating other genes in the brain at the wrong time.

 

Rett Syndrome Epidemiology Insights

Prevalent Cases
Gender-specific Prevalent Cases
Age-specific Prevalent Cases
Diagnosed and Treatable Cases

 

Table of content

1. Key Insights

2. Executive Summary of Rett Syndrome

3. Competitive Intelligence Analysis for Rett Syndrome

4. Rett Syndrome: Market Overview at a Glance

5. Rett Syndrome: Disease Background and Overview

6. Patient Journey

7. Rett Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Rett Syndrome Unmet Needs

10. Key Endpoints of Rett Syndrome Treatment

11. Rett Syndrome Marketed Products

12. Rett Syndrome Emerging Therapies

13. Rett Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Rett Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/